Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma (ONO-4059-02)
jRCT2080223590Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ono Pharmaceutical. Primary endpoints: Maximum tolerated dose (MTD), Recommended phase 2 dose (RP2D) and 1 more. Started Jul 2017; status: completed.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT2080223590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223590.